Back to Search Start Over

Phase II Study Of Erlotinib As Third-Line Monotherapy In Patients With Advanced Non-Small-Cell Lung Cancer Without Epidermal Growth Factor Receptor Mutations

Authors :
Shun Matsuura
Takafumi Suda
Takashi Yamada
Koji Yokomura
Yuichi Ozawa
Kingo Chida
Mikio Toyoshima
Toshihiro Shirai
Kazumasa Yasuda
Naoki Inui
Hideki Suganuma
Source :
C43. LUNG CANCER: DIAGNOSIS, STAGING, TREATMENT AND OUTCOMES.
Publication Year :
2012
Publisher :
American Thoracic Society, 2012.

Subjects

Subjects :
biology
business.industry
Phases of clinical research
medicine.disease
Third line
medicine
Cancer research
biology.protein
In patient
Erlotinib
Non small cell
Epidermal growth factor receptor
Lung cancer
business
medicine.drug

Details

Database :
OpenAIRE
Journal :
C43. LUNG CANCER: DIAGNOSIS, STAGING, TREATMENT AND OUTCOMES
Accession number :
edsair.doi...........20cb2b62667b6a550a5d224aea5cd329
Full Text :
https://doi.org/10.1164/ajrccm-conference.2012.185.1_meetingabstracts.a4408
Full Text Access
View/download PDF

Tools

Authors Abstract Subjects Details